In the short term we are also expecting another deal with Big Pharma. This must be the CD40 ligand work - this could be of the order of the anti-microbials deal.
Near the end of the year we are expecting the second phase of the Roche deal.
PLUS - there is the potential for positive surprises in terms of new deals for discovery targets outside of existing discovery work (which is the reason the Roche deal was so significant).
Phylogica has brilliant prospects.
delivery 101, page-4
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $606.5M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 12.5¢ | $17.86K | 137.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 1081168 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 505604 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |